An insulin pump is a small wearable device that delivers continuous subcutaneous insulin from a refillable reservoir, replacing the need for multiple daily injections. The leading systems in 2025 — Tandem t:slim X2, Omnipod 5, Medtronic MiniMed 780G, and Beta Bionics iLet — are FDA-cleared automated insulin delivery (AID) platforms that pair with a continuous glucose monitor and adjust basal insulin automatically. Pumps are mostly used for type 1 diabetes but are increasingly approved for intensively managed type 2 diabetes.
How Insulin Pumps Work
A pump holds rapid-acting insulin (typically Humalog, NovoLog, Fiasp, or Apidra) in a reservoir or pod, connected to the body through a thin cannula inserted just under the skin. Tubed pumps connect via flexible plastic tubing to an infusion set on the abdomen or hip; tubeless or patch pumps stick directly to the skin and are controlled wirelessly. The pump delivers tiny continuous doses (basal) all day, plus larger doses (bolus) at meals and to correct high glucose. With CGM integration, modern AID systems use an algorithm to raise or lower basal automatically based on real-time glucose trends. The user still has to count carbs and announce meals for accurate boluses, which is why these systems are called hybrid closed loop.
The Four Major AID Systems in 2025
All four leading U.S. systems are FDA-cleared, work with at least one integrated CGM, and use proprietary algorithms. They differ in form factor, default settings, and ecosystem.
| System | Form | Algorithm | Compatible CGMs | Smartphone Control |
|---|---|---|---|---|
| Tandem t:slim X2 with Control-IQ | Tubed, touchscreen | Control-IQ | Dexcom G6, G7 | Bolus from phone (iOS/Android) |
| Omnipod 5 | Tubeless patch pod | SmartAdjust | Dexcom G6, G7, Libre 2 Plus | Yes — phone or controller |
| Medtronic MiniMed 780G | Tubed | SmartGuard with auto-correction | Guardian 4, Simplera | App view; bolus from pump |
| Beta Bionics iLet | Tubed, simplified | Bionic pancreas — no carb counting required | Dexcom G6, G7 | Limited app |
Tandem t:slim X2 with Control-IQ
The t:slim X2 is a slim tubed pump with a color touchscreen and remote software updates. The Control-IQ algorithm uses Dexcom CGM data to adjust basal every five minutes and deliver automatic correction boluses for predicted highs. It has dedicated sleep and exercise activity profiles. Tandem received FDA clearance for full bolus dosing from a phone app in 2024, which removed one of the few remaining advantages of standalone controllers.
Insulet Omnipod 5
Omnipod 5 is the only fully tubeless AID in the U.S. Each pod sticks to the skin for up to three days, with an integrated cannula and a wireless connection to a phone or handheld controller. The SmartAdjust algorithm runs on the pod itself, so the system continues to adjust basal insulin even if the phone is out of range. Omnipod 5 is FDA-cleared for type 1 and type 2 diabetes and for use with both Dexcom G6/G7 and Abbott FreeStyle Libre 2 Plus, the broadest CGM compatibility of any U.S. AID.
Medtronic MiniMed 780G
The 780G uses Medtronic’s SmartGuard algorithm with a 100 mg/dL target and automatic correction boluses every five minutes. It pairs with the Guardian 4 sensor and the newer Simplera CGM. Medtronic emphasizes the 780G’s ability to drive more time in range with minimal user input, and clinical data show meaningful A1C and time-in-range improvements when meal announcements are routine.
Beta Bionics iLet
The iLet is the most recent entrant and takes a radically simplified approach: no carb counting and no basal/bolus settings. The user enters body weight at setup and announces meals as “usual,” “less,” or “more.” The bionic pancreas algorithm handles everything else. It is FDA-cleared for type 1 diabetes in adults and children age 6 and older. The iLet appeals to people who find traditional pump programming overwhelming.
Who Benefits Most From a Pump
Pumps are the standard of care for many people with type 1 diabetes, particularly those who pursue tight control, have brittle glucose patterns, or experience hypoglycemia unawareness. People with insulin-treated type 2 diabetes who do not reach A1C goals on MDI may also benefit, with FDA clearances now covering several systems for T2D. Strong candidates count carbs at meals (with the iLet as a notable exception), wear a CGM consistently, and have insurance coverage or a path to afford the device and ongoing supplies. People who travel frequently, exercise a lot, or have unpredictable meal timing often see the largest quality-of-life gains. According to the ADA Standards of Care, AID systems are recommended for many adults with type 1 diabetes, and shared decision-making is emphasized for type 2.
Practical Considerations
Pumps require regular site changes (every 2 to 3 days), reservoir refills, infusion set checks, and a backup plan with pens or syringes for technical failures. Skin reactions to adhesives are common; rotating sites and using barrier products help. Insurance coverage varies — Medicare now covers most AID systems for type 1 diabetes when criteria are met. Costs without insurance can run several thousand dollars upfront for the device and several hundred per month for supplies. For broader treatment context, see our treatment hub and the prediabetes overview for upstream prevention.
The Bottom Line
Insulin pumps and AID systems have transformed diabetes management in the past decade, with four U.S. platforms now competing on form factor, algorithm style, and CGM compatibility. None is universally “best” — the right pump depends on whether you prefer tubeless or tubed, which CGM you wear, how much manual control you want, and what your insurance covers. Talk to an endocrinologist or diabetes care and education specialist about a hands-on demo before deciding.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
